Clinical Trials Sponsored by Gmax Biopharm LLC.

Total 59 results

Gmax Biopharm LLC.

Recruiting

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, China
Gmax Biopharm Australia Pty Ltd.

Completed

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Overweight and Obesity

Australia
Gmax Biopharm Australia Pty Ltd.
Metaclinical; Syneos Heath

Completed

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers

Pulmonary Arterial Hypertension

Australia
Denovo Biopharma LLC

Completed

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

Schizophrenic Disorders

United States
Denovo Biopharma LLC

Completed

A Study of Safety and Tolerability in Subjects With Schizophrenia

Schizophrenia

United States
Denovo Biopharma LLC

Terminated

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Schizophrenia

Germany, Spain, United States, Belgium, France, Sweden, Austria, Poland, Puerto Rico, Romania
Denovo Biopharma LLC

Completed

A Study of LY2140023 in Healthy Males and Females

Healthy Volunteers

United Kingdom
Denovo Biopharma LLC

Completed

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

Schizophrenia

Russian Federation
Veloce BioPharma LLC

Active, not recruiting

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

Warts

United States
Veloce BioPharma LLC

Completed

A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum

Molluscum Contagiosum

United States
Denovo Biopharma LLC

Completed

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Schizophrenia

United States, Mexico, Germany, Russian Federation
Denovo Biopharma LLC

Terminated

A Study of LY2140023 in Patients With Schizophrenia

Schizophrenia

United States, Mexico, Russian Federation, Puerto Rico, Ukraine
Denovo Biopharma LLC

Completed

A Physical Dependence Study in Schizophrenia

Schizophrenia

United States, Greece
Denovo Biopharma LLC

Completed

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Schizophrenia

Italy, United States, Spain, Israel
Denovo Biopharma LLC

Withdrawn

A Study of LY2140023 in Healthy Participants

Healthy Participants

Switzerland
Veloce BioPharma LLC

Completed

A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Chemotherapy-Associated Paronychia

United States
Biopharma Plasma LLC

Recruiting

Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia

Ukraine
Denovo Biopharma LLC

Completed

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Glioblastoma

United States, China, Canada
Denovo Biopharma LLC

Completed

A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression (ENLIGHTEN)

Treatment Resistant Depression

United States, Canada
Denovo Biopharma LLC

Completed

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

Diffuse Large B-Cell Lymphoma

United States, China
Denovo Biopharma LLC

Completed

A Study of LY2140023 in Hepatically-Impaired Participants

Hepatic Insufficiency

Germany, Hungary
Denovo Biopharma LLC

Completed

A Study of LY2140023 in Healthy Participants

Healthy Volunteer Study

United Kingdom
Denovo Biopharma LLC

Completed

A Study of LY2140023 in Healthy Participants

Healthy Participants

United Kingdom
Denovo Biopharma LLC

Terminated

A Study in Schizophrenic Patients

Schizophrenia

Japan, Taiwan, Korea, Republic of
Veloce BioPharma LLC

Completed

ALC-919 For The Treatment Of Common Warts

Verruca Vulgaris

United States
Zenas BioPharma (USA), LLC

Recruiting

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

Warm Autoimmune Hemolytic Anemia

Japan, Taiwan, United States, Spain, Italy, United Kingdom, Poland, Turkey
Zenas BioPharma (USA), LLC

Active, not recruiting

A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis

Rheumatoid Arthritis | Healthy Volunteers

New Zealand, Australia
Zenas BioPharma (USA), LLC

Active, not recruiting

A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants

Healthy Volunteers

New Zealand
Zenas BioPharma (USA), LLC

Recruiting

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease (INDIGO)

IgG4 Related Disease

United States, Korea, Republic of, Spain, Japan, France, Poland, Taiwan, Italy, United Kingdom, Argentina, Netherlands, Turkey, Hong Kong, Sweden, Hungary, Germany, Mexico
Zenas BioPharma (USA), LLC

Active, not recruiting

Study of ZB001 in Chinese Patients With Thyroid Eye Disease

Thyroid Eye Disease

China
Zenas BioPharma (USA), LLC

Completed

A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects

Healthy Volunteers

China
Topical Remedy
Benu BioPharma, LLC

Completed

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores

Recurrent Herpes Labialis

United States
CardioKine Inc.
Cardiokine Biopharma, LLC

Completed

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Congestive Heart Failure

United States
Cue Biopharma
Merck Sharp & Dohme LLC

Active, not recruiting

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Hyponatremia With Normal Extracellular Fluid Volume

United States, Canada, Germany, India, Poland, Belgium
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Euvolemic Hyponatremia

United States, Israel, India, Mexico, Peru, Belgium, Czech Republic, Italy
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

Hyponatremia With Excess Extracellular Fluid Volume | Hyponatremia With Normal Extracellular Fluid Volume

United States
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Healthy

United States
Merck Sharp & Dohme LLC
Array BioPharma

Completed

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)

Metastatic Colorectal Cancer

United States, Canada
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

Hyponatremia

Italy, United States, Argentina, Israel, Poland, Spain, Chile, India, Canada, Czech Republic, Germany, Romania, Russian Federation, Slovakia, Switzerland
SCRI Development Innovations, LLC
CTI BioPharma

Completed

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Withdrawn

International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia

Hypervolemic Hyponatremia
SCRI Development Innovations, LLC
CTI BioPharma

Completed

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

Multiple Myeloma
Lotus Clinical Research, LLC
iX Biopharma Ltd.

Completed

A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction

Pain

United States
Matinas BioPharma Nanotechnologies, Inc.
MB Clinical Research and Consulting LLC; Matinas Biopharma, Inc

Completed

Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (ENHANCE-IT)

Hypertriglyceridemia

United States
Lyvgen Biopharma Holdings Limited
Merck Sharp & Dohme LLC

Recruiting

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Cancer

United States
Topical Remedy
Benu BioPharma, LLC; Accelovance; Optimal Research

Completed

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores

Recurrent Herpes Labialis

United States
Lytix Biopharma AS
ICON plc; Theradex

Completed

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Melanoma | Lymphoma | Cancer | Breast Cancer | Head and Neck Cancer | Triple-Negative Breast Cancer

United Kingdom, France, Norway, Belgium, Italy
Adlai Nortye Biopharma Co., Ltd.
Merck Sharp & Dohme LLC

Active, not recruiting

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Cervical Cancer | Triple-negative Breast Cancer | NSCLC, Squamous or Non-Squamous | Urothelial Carcinoma of the Bladder | Microsatellite Stable (MSS) Colorectal Cancer (CRC)

United States, France
Abinopharm, Inc
ProRelix Services LLP

Completed

To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults

Aging

India

Clinical Trials Sponsored by Gmax Biopharm LLC.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations